Marinus Pharmaceuticals (NASDAQ:MRNS) Given Overweight Rating at Cantor Fitzgerald

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “overweight” rating reissued by investment analysts at Cantor Fitzgerald in a report issued on Tuesday, Benzinga reports. They presently have a $13.00 price objective on the biopharmaceutical company’s stock.

Several other research firms also recently weighed in on MRNS. JMP Securities reiterated a “market outperform” rating and issued a $10.00 target price on shares of Marinus Pharmaceuticals in a research note on Monday. LADENBURG THALM/SH SH lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. StockNews.com raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 18th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. Finally, Truist Financial reiterated a “buy” rating and set a $10.00 price objective on shares of Marinus Pharmaceuticals in a research note on Tuesday, June 18th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.83.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ MRNS opened at $1.63 on Tuesday. The company has a current ratio of 2.28, a quick ratio of 2.15 and a debt-to-equity ratio of 5.68. The stock has a fifty day simple moving average of $1.38 and a two-hundred day simple moving average of $2.73. Marinus Pharmaceuticals has a 1-year low of $1.05 and a 1-year high of $11.26. The firm has a market cap of $89.54 million, a price-to-earnings ratio of -0.62 and a beta of 1.13.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.01). Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%. The firm had revenue of $8.06 million for the quarter, compared to the consensus estimate of $9.05 million. During the same quarter in the previous year, the company posted ($0.61) EPS. Analysts anticipate that Marinus Pharmaceuticals will post -1.88 earnings per share for the current year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of institutional investors have recently made changes to their positions in MRNS. Point72 DIFC Ltd bought a new position in Marinus Pharmaceuticals in the second quarter valued at $28,000. SG Americas Securities LLC purchased a new position in Marinus Pharmaceuticals in the 2nd quarter worth approximately $34,000. AQR Capital Management LLC grew its holdings in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Marinus Pharmaceuticals in the first quarter worth approximately $384,000. Finally, Trexquant Investment LP purchased a new position in shares of Marinus Pharmaceuticals in the fourth quarter worth $553,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.